Literature DB >> 24722891

Standards of practice for superficial femoral and popliteal artery angioplasty and stenting.

Konstantinos Katsanos1, Gunnar Tepe, Dimitris Tsetis, Fabrizio Fanelli.   

Abstract

This is a Standards of Practice document endorsed by CIRSE. The authors performed a literature review and provide recommendations and quality improvement guidelines based on the most recent and highest level of evidence available to date on the field of Superficial Femoral and Popliteal Artery Angioplasty and Stenting. Standards for the use of basic and more advanced endovascular techniques in the femoropopliteal arteries are reported and relevant aspects of case selection, imaging, follow-up, and overall patient management are presented to guide endovascular practice in Europe.

Entities:  

Mesh:

Year:  2014        PMID: 24722891     DOI: 10.1007/s00270-014-0876-3

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  22 in total

Review 1.  Clopidogrel Resistance in Lower Extremity Arterial Endovascular Interventions.

Authors:  Kyle M Markel; Efthymios D Avgerinos
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

Review 2.  Treating femoropopliteal disease: established and emerging technologies.

Authors:  Athanasios Diamantopoulos; Konstantinos Katsanos
Journal:  Semin Intervent Radiol       Date:  2014-12       Impact factor: 1.513

3.  CIRSE Standards of Practice on Below-the-Knee Revascularisation.

Authors:  Stavros Spiliopoulos; Costantino Del Giudice; Marco Manzi; Lazaros Reppas; Thomas Rodt; Raman Uberoi
Journal:  Cardiovasc Intervent Radiol       Date:  2021-06-25       Impact factor: 2.740

Review 4.  Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2015-11-01

5.  Starclose SE® hemostasis after 6F direct antegrade superficial femoral artery access distal to the femoral head for peripheral endovascular procedures in obese patients.

Authors:  Stavros Spiliopoulos; Panagiotis Kitrou; Nikolaos Christeas; Dimitris Karnabatidis
Journal:  Diagn Interv Radiol       Date:  2016 Nov-Dec       Impact factor: 2.630

6.  A predictive multiscale model of in-stent restenosis in femoral arteries: linking haemodynamics and gene expression with an agent-based model of cellular dynamics.

Authors:  Anna Corti; Monika Colombo; Jared M Rozowsky; Stefano Casarin; Yong He; Dario Carbonaro; Francesco Migliavacca; Jose F Rodriguez Matas; Scott A Berceli; Claudio Chiastra
Journal:  J R Soc Interface       Date:  2022-03-30       Impact factor: 4.118

7.  Use of Atherectomy During Index Peripheral Vascular Interventions.

Authors:  Caitlin W Hicks; Courtenay M Holscher; Peiqi Wang; Chen Dun; Christopher J Abularrage; James H Black; Kim J Hodgson; Martin A Makary
Journal:  JACC Cardiovasc Interv       Date:  2021-03-22       Impact factor: 11.075

Review 8.  Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.

Authors:  Konstantinos Katsanos; Stavros Spiliopoulos; Prakash Saha; Athanasios Diamantopoulos; Narayan Karunanithy; Miltiadis Krokidis; Bijan Modarai; Dimitris Karnabatidis
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

Review 9.  Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK.

Authors:  Konstantinos Katsanos; Benjamin P Geisler; Abigail M Garner; Hany Zayed; Trevor Cleveland; Jan B Pietzsch
Journal:  BMJ Open       Date:  2016-05-09       Impact factor: 2.692

10.  Continuously Grooved Stent Struts for Enhanced Endothelial Cell Seeding.

Authors:  Marja Ter Meer; Willeke F Daamen; Yvonne L Hoogeveen; Gijs J F van Son; Jeremy E Schaffer; J Adam van der Vliet; Leo J Schultze Kool; Lambertus P van den Heuvel
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-03       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.